Anton Pozniak
Overview
Explore the profile of Anton Pozniak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
4167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azzi A, Chartouni C, Sakr C, Ibrahim R, Bou Chebel Z, Haddad E, et al.
J Med Educ Curric Dev
. 2024 Dec;
11:23821205241307735.
PMID: 39717222
Objective: In Lebanon, HIV prevalence among key populations such as men who have sex with men is high at 12%, warranting a need for targeted healthcare efforts. Pre-exposure prophylaxis (PrEP)...
2.
Ombajo L, Penner J, Nkuranga J, Omodi V, Otieno E, Ndinya F, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39589132
Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor-based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference...
3.
Penner J, Ombajo L, Nkuranga J, Otieno E, Nyakoe D, Wanjohi R, et al.
HIV Med
. 2024 Nov;
26(3):382-389.
PMID: 39569696
Objectives: Our objective was to evaluate bone mineral density (BMD) among older people living with HIV at the time of enrolment into a clinical trial in Kenya. Methods: The bictegravir/emtricitabine/tenofovir...
4.
Moyle G, Assoumou L, de Castro N, Post F, Curran A, Rusconi S, et al.
Lancet HIV
. 2024 Feb;
11(3):e156-e166.
PMID: 38417976
Background: The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to...
5.
Payagala S, Pozniak A
Clin Dermatol
. 2024 Feb;
42(2):119-127.
PMID: 38387533
The global burden of HIV remains a formidable challenge, affecting millions. Despite significant progress in understanding, treatment, and prevention , HIV/AIDS continues to exert a substantial impact on personal and...
6.
Orkin C, Antinori A, Rockstroh J, Moreno-Guillen S, Martorell C, Molina J, et al.
AIDS
. 2024 Feb;
38(7):983-991.
PMID: 38349226
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy. Design: Studies 1489 (NCT02607930) and 1490 (NCT02607956) were...
7.
Abdul R, Wit T, Martelli G, Costigan K, Katambi P, Pozniak A, et al.
Trop Med Int Health
. 2024 Jan;
29(4):309-318.
PMID: 38279832
Background: HIV services in Tanzania are facility-based but facilities are often overcrowded. Differentiated care models (DCM) have been introduced into the National Guidelines. We piloted a Community Health Worker (CHW)-led...
8.
Nightingale S, Cinque P, Dravid A, Dreyer A, Gisslen M, Joska J, et al.
Nat Rev Neurol
. 2024 Jan;
20(2):129-130.
PMID: 38228907
No abstract available.
9.
Liegeon G, Duffy A, Brooks C, Honour H, Pozniak A, Molina J
HIV Med
. 2023 Dec;
25(3):353-360.
PMID: 38040445
Objectives: We conducted a survey to evaluate HIV pre-exposure prophylaxis (PrEP) practices in a European clinical research network on HIV, hepatitis, and global infectious diseases (NEAT ID). Methods: An online...
10.
Gonzalez-Cordon A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al.
J Antimicrob Chemother
. 2023 Aug;
78(9):2361-2365.
PMID: 37539492
Background: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed...